NON ALCOHOLIC FATTY LIVER DISEASE.
Conditions
Interventions
Intervention 1: Intervention group 1:50000 U vitamin D3 (cholecalciferol) pearl (Zahravi Pharmacutical Co) per week for 3 months. Intervention 2: Intervention group 2 : Intervention group 2: 0.25 mg c
Treatment - Drugs
Intervention group 1:50000 U vitamin D3 (cholecalciferol) pearl (Zahravi Pharmacutical Co) per week for 3 months
Intervention group 2 : Intervention group 2: 0.25 mg calcitriol (1,25 dihydroxycholecalciferol) pearl (Zahravi Pharmacutical Co) per day for 3 months.
Control group: Placebo capsule (Zahravi Pharmacutical Co) /one per week for 3 months
Sponsors
Vice Chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: men and women aged between 20 and 75 years with presence of hepatic steatosis diagnosed by ultrasound (US) Exclusion criteria: Patients with liver cirrhosis; patients with hepatitis B or hepatitis C; patients with alcohol consumption (> 10 gr/ day); patients with autoimmune hepatitis; Wilson’s disease and hemochromatosis; known cancer; nephrolithiasis; nephrocalcinosis; chronic renal failure; hypercalcemia; hypercalciurea; pregnancy; lactation; patients receiving estrogen; tamoxifen; methotrexate; amiodarone; tetracycline and those receiving vitamin D and calcium supplementations in previous 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver enzymes. Timepoint: begining of the study-3 months after. Method of measurement: biochemicl kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile and plasma glucose. Timepoint: begining of the study- 3 months later. Method of measurement: Biochemical kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmohammad hossein dabaghmanesh
Eendocrinology and metabolism research center
Outcome results
None listed